$3.21
2.23%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
IL0011839383
Symbol
DRTS

Alpha Tau Medical Stock price

$3.16
+0.11 3.61% 1M
+0.42 15.33% 6M
+0.06 1.94% YTD
+0.93 41.70% 1Y
-6.31 66.63% 3Y
-6.94 68.71% 5Y
-6.94 68.71% 10Y
-6.94 68.71% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.02 0.64%
ISIN
IL0011839383
Symbol
DRTS

Key metrics

Basic
Market capitalization
$267.7m
Enterprise Value
$221.5m
Net debt
positive
Cash
$51.6m
Shares outstanding
70.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
4.8
Financial Health
Equity Ratio
72.7%
Return on Equity
-50.7%
ROCE
-51.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-44.9m
EBIT
$-36.9m | $-41.8m
Net Income
$-32.5m | $-33.8m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -28.6%
EBIT
-4.1% | -15.9%
Net Income
-12.1% | -6.6%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
-
Short interest
0.1%
Employees
125
Rev per Employee
$0.0
Show more

Is Alpha Tau Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Alpha Tau Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Alpha Tau Medical forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Alpha Tau Medical forecast:

Buy
90%
Hold
10%

Financial data from Alpha Tau Medical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.18 9.18
3% 3%
-
- Research and Development Expense 28 28
4% 4%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -37 -37
4% 4%
-
Net Profit -32 -32
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alpha Tau Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alpha Tau Medical Stock News

Neutral
GlobeNewsWire
13 days ago
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -
Neutral
GlobeNewsWire
3 months ago
- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group analys e s, and positive safety profile -
Neutral
GlobeNewsWire
3 months ago
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq:  DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company's Board of Directors (“Board”). Th...

Company Profile

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Uzi Sofer
Employees 125
Founded 2015
Website www.alphatau.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today